|Day Low/High||85.33 / 86.08|
|52 Wk Low/High||64.03 / 88.76|
There are nearly too many surging sectors to count.
ABT could be on course for 10% earnings growth this year, but will investors reward the company with a higher share price?
Start 2017 on the right foot by selling your holdings in these five stocks.
The Federal Trade Commission says Abbott Laboratories can proceed with its proposed $25 billion acquisition of St. Jude Medical.
Here is a look at some stocks that are poised for excellent dividend returns in 2017.
Look for ABT's declining trend to continue a while longer.
"You see, in this world there's two kinds of people, my friend: Those with loaded guns and those who dig. You dig." -- Blondie in "The Good, the Bad and the Ugly." I did very little today. Markets were higher from the get-go and seemed "stuck" nea...
Shares of the medical-device giant were climbing after unveiling strong earnings.
Political pressure is weighing on drug and medical device stocks including Abbott Labs and St. Jude, says Jim Cramer.
St. Jude's warning about battery risks in its implanted heart devices are big but will likely not disrupt its deal with Abbott Labs.
U.S. stocks ended Friday's session lower as a crude oil selloff pressures the energy sector and nerves over next week's Federal Reserve meeting peak.
The signs that have warned of a possible market reversal only have become more extreme.
Oil began to rebound Wednesday from steep declines earlier this week.
They should wait until the rally appears to be running out of steam in order to go in on the short side.
The M&A activity is an incredible and a welcome sign.
Jim Cramer is bullish on Abbott Laboratories' acquisition of St. Jude Medical.
U.S. stocks dropped on Thursday, as first quarter gross domestic product came in weaker than expected.
Movement has become difficult after weeks of advances, which suggests a downturn may be near.
Jim Cramer believes Abbott Labs' CEO Miles White is doing a terrific job of making the company better.
The Russell 2000's failure to follow the S&P and Dow's lead is only one reason for concern.
Shares of Alere soared on Monday on word that Abbott Labs would acquire the company in a deal valued at $7.9 billion.
Two significant, but subtle forces may threaten the group in the next 12 months.
The merged company can become multiple companies.